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ABSTRACT
Purpose. Pathologic downstaging following chemotherapy
for stage III-N2 NSCLC is a well-known positive prognostic
indicator. However, the predictive factors for locoregional
recurrence (LRR) in these patients are largely unknown.
Methods. Between 1998 and 2008, 153 patients with clin-
ically or pathologically staged III-N2 NSCLC from two
cancer centers in the United States were treated with
induction chemotherapy and surgery. All had pathologic N0-
1 disease, and none received postoperative radiotherapy.
LRR were defined as recurrence at the surgical site, lymph
nodes (levels 1–14 including supraclavicular), or both.
Results. Median follow-up was 39.3 months. Pretreatment
N2 status was confirmed pathologically (18.2 %) or by
PET/CT (81.8 %). Overall, the 5-year LRR rate was
30.8 % (n = 38), with LRR being the first site of failure in
51 % (22/?99877943). Five-year overall survival for
patients with LRR compared with those without was 21
versus 60.1 % (p \ 0.001). Using multivariate analysis,
significant predictors for LRR were pN1 disease at time of
surgery (p \ 0.001, HR 3.43, 95 % CI 1.80–6.56) and a
trend for squamous histology (p = 0.072, HR 1.93, 95 %
CI 0.94–3.98). Five-year LRR rate for pN1 versus pN0
disease was 62 versus 20 %. Neither single versus multi-
station N2 disease (p = 0.291) nor initial staging technique
(p = 0.306) were predictors for LRR. N1 status also was
predictive for higher distant recurrence (p = 0.021, HR
1.91, 95 % CI 1.1–3.3) but only trended for poorer survival
(p = 0.123, HR 1.48, 95 % CI 0.9–2.44).
Conclusions. LRR remains high in resected stage III-N2
NSCLC patients after induction chemotherapy and nodal
downstaging, particularly in patients with persistent N1 disease.
For patients with stage III NSCLC, multimodality
therapy remains the standard of care. Approximately 10 %
of all NSCLC cases present as stage IIIA-N2, and for these
patients, disease control and overall survival (OS) continue
to be poor, with 5-year survival rates of 23 %.1 Several
randomized trials have demonstrated local recurrence rates
of 11–34 % among patients with stage I–III disease after
surgery alone,2–4 suggesting additional consolidative ther-
apies may be needed to control local disease. Earlier
studies looking at consolidative therapies in addition to
surgery in patients with stage III-N2 found this population
to be quite heterogenous, making it difficult to determine
the best treatment approach for these patients.
Several randomized trials and meta-analysis have
demonstrated a survival benefit with neoadjuvant chemo-
therapy with surgery versus surgery alone.5–8 Most of the
benefit of induction chemotherapy is restricted to more
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locally advanced, stage II–III patients.9 On further analysis,
several studies found that patients with mediastinal nodal
response after induction chemotherapy have improved
outcomes.7,10,11 In one trial,7 induction chemotherapy
produced 3- and 5-year survival rates of 67.7 and 51.6 %
for patients with disease downstaged to pN0 compared with
38.5 and 17.6 % for those with pN1-3 disease. A study by
the Swiss SAKK Group11 concluded that patients with
nodal downstaging to N0-1 after induction therapy had
improved disease-free survival and OS (HR 0.26) com-
pared with patients with mediastinal lymph node
involvement. The median time to local relapse comparing
persistent pN2 versus pN0-1 was 14.4 versus 43.8 months.
In their most recent update, they reported 5-year locore-
gional failure (LRF) rates as high as 60 % in the entire
study population, including those with or without nodal
downstaging. In those patients with pathologic response to
chemotherapy, there was a significant reduction in distant
metastasis. Although several other trials have demonstrated
the prognostic importance of mediastinal nodal downstag-
ing or pathologic response to induction chemotherapy,
local failure rates specifically for the nodal downstaged
group are rarely reported, especially in those patients who
did not receive postoperative radiotherapy (PORT).
In this study, we performed a retrospective analysis of
the treatment outcomes of patients treated at two major
cancer centers to determine predictors for locoregional
recurrence for patients with clinical stage III-N2 disease
who undergo nodal downstaging after induction chemo-
therapy at the time of surgery. We hypothesized that there
are certain patient and tumor characteristics that would be
predictive for higher local recurrence and thus may




Chart review of all patients treated with induction che-
motherapy followed by surgery between 1998 through
2008 was performed at The University of Texas MD
Anderson Cancer Center and Memorial Sloan Kettering
Cancer Center. We excluded patients with tumors not of
non-small cell origin, having persistent N2 disease at the
time of surgery, and death within 1 month of surgery. We
identified 179 patients with stage III NSCLC (N2) who fit
the above criteria. At the time of surgery, all patients in the
study had documented downstaged nodal disease, either to
N0 or N1. In addition, 26 patients who received PORT
after surgery were excluded from the analysis, largely due
to the relatively small sample size and were biased for
high-risk characteristics (positive margins, bulky tumor).
Based on these guidelines, 153 patients were identified and
combined for this analysis: MD Anderson (n = 56) and
Memorial Sloan Kettering (n = 97). This post hoc analysis
was reviewed and approved by the institutional review
boards of at both cancer centers.
Treatment and Response Assessment
Both institutions followed the same guidelines in pre-
paring and gathering patient and treatment characteristics.
All patients had clinically or pathologically proven N2
involvement before starting induction chemotherapy.
Clinically, patients were documented to have node-positive
disease if the nodes were [1 cm in their shortest dimen-
sion, if the standardized uptake value (SUV) on positron
emission tomography (PET) was[4.0, or both. The choice
of neoadjuvant chemotherapy was at the discretion of the
treating medical oncologist. All patients underwent surgi-
cal resection at MD Anderson or at Memorial Sloan
Kettering Cancer Center. Tumor grade and histology were
confirmed by pathological analysis at the time of surgery.
Some patients received additional treatments, such as
adjuvant chemotherapy but not PORT. The majority of
patients (n = 131) received no additional chemotherapy
after surgery. The Response Evaluation Criteria in Solid
Tumors (RECIST) v1.1 was used to assess response to
induction chemotherapy according to the change in the
largest diameter of the tumor on PET/CT imaging.
Local-Regional and Distant Recurrence
Local-regional recurrences were defined as those at the
surgical site, at the anastomotic or bronchial stump, or in
the local-regional lymph nodes (levels 1–14, including
supraclavicular). Cervical and abdominal lymph node dis-
ease was considered distant recurrence. Disease recurrence
was verified by either imaging (PET/CT) or biopsy. Time
to recurrence was based on the date of imaging- or biopsy-
proven disease recurrence and the original date of surgery.
Follow-up and Survival
The date of diagnosis was based on the date of biopsy-
proven NSCLC. This was compared with the last contact
date, which was the last known date of the patients’ vital
status and disease status, to calculate follow-up time. OS
was calculated based on the initial date of diagnosis. A
total of five patients had missing data on disease recurrence
(either local-regional or distant or both) due to poor follow-
up. Nine patients had an unknown vital status.
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Statistical Analysis
All statistical analyses were performed using the SPSS
V17.0 (SPSS Inc., Chicago, IL). Pearson two-sided, chi-
square tests were used to evaluate patient- and treatment-
related differences between patients with or without local
and distant recurrences. Univariate Cox regression analysis
was performed using death, LRF, or DF as outcomes with a
significance level of p \ 0.05. Covariates that were sig-
nificant at p \ 0.25 were included in the multivariable Cox
regression. Backward stepwise Wald elimination at
p = 0.1 was used to establish the final model. Multivariate
analysis was performed separately for overall survival,
local, and distant metastasis. Patients with incomplete data
were excluded from the multivariate analysis. Survival
functions were calculated according to the Kaplan–Meier
method, and differences were assessed with the log-rank
test.
RESULTS
Patient and Treatment Characteristics
From February 1998 to December 2008, 153 patients
with clinically or pathologically staged III-N2 NSCLC
from two cancer centers in the United States were treated
with induction chemotherapy followed by surgery and
found to have pathologically downstaged nodal disease at
the time of their surgery. Median follow-up time for all
patients was 39.3 (range 21.2–79) months. The 5-year
overall survival for this population was 49.6 %. Patient
characteristics are shown in Table 1. The median age was
65 (range 41–83) years; a slight majority were male
(77.1 %), and most patients had good performance status
(KPS C 80). Nodal status before induction chemotherapy
was staged by mediastinoscopy (15.7 %) or PET/CT
(84.3 %). Most patients presented with T2 disease
(63.4 %), single station N2 involvement (60.8 %), with
adenocarcinoma being the most common histology found
(54.2 %).
The median number of induction chemotherapy cycles
was three (range 2–8), with 83 % of patients receiving a
platinum–taxane doublet regimen. In this cohort, no
patients received PORT; however, a small subset received
adjuvant chemotherapy (n = 22, 14.4 %; Supplemental
Table 1). The two most common reasons for receipt of
systemic dose adjuvant chemotherapy were multilevel N2
disease, clinical T4 disease on initial presentation, or
institutional protocols requiring additional adjuvant che-
motherapy. Overall, 131 (85.6 %) patients did not receive
postoperative chemotherapy.
TABLE 1 Patient characteristics
Characteristics No. of patients (%)
Age
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Local-Regional Failure Patterns
The 5-year local-regional failure (LRF) rate was 30.8 %
(n = 38), with LRF being the first site of failure in 51 % of
these individuals (22/43). All local recurrences in the study
population occurred within 5 years, with the latest recur-
rence occurring 45.6 months after the date of surgery. On
univariate analysis, LRF was significantly higher in
patients with pathologic N1 compared with N0 disease (at
time of surgery) (HR 3.478, 95 % CI 1.837–6.587,
p \ 0.001; Fig. 1). Additional predictors for LRF included
squamous cell histology (HR 2.219, 95 % CI 1.086–4.535,
p = 0.048). Neither single versus multistation N2 disease
(HR 0.692, 95 % CI 0.349–1.371, p = 0.291) nor initial
staging by mediastinoscopy versus PET/CT (HR 0.665,
95 % CI 0.305–1.451, p = 0.306) were predictors for LRF.
Multivariate analysis demonstrated that only a pathologic
N1 (at surgery) was associated with higher LRF rates (HR
3.435, 95 % CI 1.798–6.561, p \ 0.001). There was only a
trend for greater LRF rates in tumors with squamous cell
histology (HR 1.934, 95 % CI 0.94–3.977, p = 0.073;
Table 2).
Distant Failure Patterns
The probability of being distant recurrence-free at
5 years was 57.7 %; those with and without LRF had a
5-year distant recurrence-free disease of 26.3 and 69.3 %,
respectively (p \ 0.001; Fig. 2a). Under univariate analy-
sis, the only predictor of higher distant failure (DF) rates
was in those with pathologic N1 stage at the time of sur-
gery (HR 1.909, 95 % CI 1.104–3.304, p = 0.021;
Fig. 2b). In multivariate analyses, the pathologic N1
stage remained a significant independent predictor for
higher distant failures (HR 1.909, 95 % CI 1.104–3.304,
p = 0.021).
Overall Survival
Five-year OS in our study cohort was 49.6 %; those with
or without LRF had a 5-year OS of 21 % compared with
60.1 % (p = 0.001; Fig. 2c). Median survival for pN1
versus pN0 was 37.5 months compared with 62.8 months.
Univariate analysis revealed that pathologic T4 disease (at
surgery) was associated with a worse OS (HR 14.316,
95 % CI 1.717–119.327, p = 0.014). However, pathologic
N0 versus N1 disease (at surgery) was not significantly
associated with OS (HR 1.344, 95 % CI 0.821–2.2,
p = 0.237; Fig. 2d). Higher pathologic T stage continued
to be significant under multivariate analysis (Table 3).
Overall Recurrence Patterns
Most local regional recurrences appeared in the medi-
astinal (92.1 %) and hilar lymph nodes (23.7 %). Distant
failures were the most common sites of failure in this group
of patients (38.6 %). Most common site of distant metas-
tasis was the brain (42.4 %) followed by the lung (22 %).
Slightly more than half of the population had no disease
relapse (51 %; Supplemental Table 2).
TABLE 1 continued
Characteristics No. of patients (%)
No 79 (51.6)
Unknown 31 (20.3)
Level of N2 involvement at surgery





RECIST response evaluation criteria in solid tumors
FIG. 1 Kaplan–Meier curves illustrating cumulative locoregional
(LR) recurrence free probability in pathologically downstaged N0
versus N1 disease
TABLE 2 Multivariate analysis for locoregional failure
Covariate Frequency Hazard ratio (95 % CI) p value
Tumor histology
Adenocarcinoma 83 1.000 (NA) 0.072
Squamous cell 35 1.934 (0.94–3.977) 0.073
Other 34 0.726 (0.301–1.755) 0.477
Pathologic N status
N1 36 3.435 (1.798–6.561) \0.001
N0 116 1.000 (NA)
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DISCUSSION
This study evaluated the rate of locoregional recurrence
in patients with a pathologic response following neoadju-
vant chemotherapy. Consolidative therapy in these patients
is largely reserved for patients with bulky disease and
positive margins at the time of surgery. Currently, adjuvant
therapy for all patients with downstaged disease is not
considered standard of care, even though local tumor
failure rates continue to be high. In our study, we dem-
onstrated a LRF rate of 30.8 %. In addition, those with
pathologic N1 disease had significantly higher rates of
LRF. For these patients, additional treatment following
surgery may improve outcomes, because OS was signifi-
cantly lower in patients with locoregional recurrence.
Currently, the role for adjuvant therapy following surgery
in nodal downstaged patients is largely unknown. Although
PORT is more commonly prescribed to patients who are
found to have residual N2 disease at the time of surgery,
there is little agreement on additional radiation treatment
for those with downstaged from N2 to N0-1 disease. One
retrospective study looking at stage III-N2 disease treated
with induction chemotherapy and surgery found no dif-
ference in outcomes between pN1 or pN2 at the time of
surgery.12 Having any positive lymph nodes at the time of
surgery was found to increase significantly the risk for
recurrence (HR 1.9), suggesting those with pN1 to still be
at high risk for recurrence.
Whereas numerous studies have shown evidence for
improvement in local control with PORT, overall survival
was not demonstrated to be better. The PORT meta-anal-
ysis compiling nine randomized trials from 1966 to 1994
demonstrated a worse overall survival (HR 1.21) in stage
I–II NSCLC treated with PORT versus observation.13
However, the meta-analysis contained a heterogenous
population from multiple institutions spanning a large time
period, some of which used older and more toxic treatment
techniques. More recent data using modern radiation
a b
dc
FIG. 2 Kaplan–Meier curves
illustrating cumulative distant
metastatic-free survival in
patients with or without
locoregional recurrence (a) and
in pathologically downstaged
N0 versus N1 disease (b).
Kaplan–Meier curves
illustrating cumulative overall
survival with or without
locoregional recurrence (c) and
in downstaged N0 versus N1
disease (d)
TABLE 3 Multivariate analysis for overall survival
Covariate Frequency Hazard ratio (95 % CI) p value
Age 153 1.023 (0.996–1.051) 0.091
Pathologic T status
T0 10 1.000 (NA) 0.064
T1 71 5.934 (0.808–43.602) 0.08
T2 48 8.444 (1.15–61.981) 0.036
T3 16 8.624 (1.076–69.112) 0.042
T4 8 14.496 (1.738–120.87) 0.013
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fractionation, updated techniques, and equipment have
supported the use of PORT, because the treatment-related
mortality is much lower than expected from the older
PORT trials.14,15
The need for adjuvant treatment in downstaged patients
with proven N2 disease before induction chemotherapy
continues to be discussed. There is presently little data on
local control in patients with mediastinal downstaging
following induction chemotherapy. Whereas prospective
trials have shown mediastinal downstaging to be a positive
prognostic indicator following induction chemotherapy,
local failure rates in these patients are rarely analyzed. In
one of the earlier induction chemotherapy randomized
trials in stage III-N2 NSCLC, locoregional failure was seen
in 54 % of recurrences.5 However, the relationship
between local failures and pathologic response was not
defined in the study. Taylor et al.16 conducted a retro-
spective analysis of patients with stage IIB–IIIA NSCLC
treated with induction chemotherapy and found 5-year
actuarial local control rates to be 82 % among patients with
stage IIIA disease given PORT versus 35 % for patients
with stage IIIA disease without PORT. No difference was
observed in OS. However, this study did not report LRF
rates according to extent of nodal downstaging. In the
Swiss SAKK phase II trial,17 patients with stage III-N2
NSCLC received induction chemotherapy followed by
surgery, but only patients with R1/R2 resections or upper
mediastinal N2 disease received PORT. At 5 years, 60 %
of patients had LRF and 65 % DF, again demonstrating
high failure rates in such patients. The study however did
not report failure patterns between pN2 versus pN0-1.
Our study is limited by its retrospective nature and that
most of the disease recurrence determination was based on
radiographic imaging with pathologic confirmation only
attempted occasionally by biopsy. However, patients were
started on palliative/salvage treatments based on these
findings, with many of these patients to eventually further
progress and die of their disease. Patients who were scored
as having local recurrence had a poorer prognosis com-
pared with patients without recurrence, verifying the
validity of the initial call. The main strength of this study is
that it is one of the first multi-institutional attempts to
identify LRF rates and predictive factors in this specific
cohort. The study also provided a detailed assessment of
local-regional failure rates and patterns, which data often
are missing from many induction chemotherapy studies.
In conclusion, the high local failure rates after nodal
response in the mediastinum may suggest the need for
additional consolidative treatment, such as PORT, specifi-
cally in patients at high risk for local recurrence. Patients
who respond to induction chemotherapy may benefit the
most from local treatment. As more effective systemic
therapies are developed, there will be an even greater
importance to control local disease, especially in those at
high risk. Future clinical trials are needed to compare a
variety of consolidative treatment options to define the best
approach.
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